Liposyn III 30
"Nov. 28, 2012 -- Many pork chops and ground pork products in the U.S. may be tainted with antibiotic-resistant bacteria, including one that the USDA does not look for, a Consumer Reports study shows.
The new report also found"...
Liposyn III 30
Liposyn III 30 Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Liposyn III 30% (intravenous fat emulsion) is a source of calories and fat used in patients requiring parenteral nutrition. Where such nutrition is required for extended periods of time (more than 5 days), Liposyn III 30% is also indicated as a source of essential fatty acids to prevent or reverse biochemical changes in fatty acid composition of plasma lipids (elevated triene/tetraene ratio) and the clinical manifestations of essential fatty acid deficiency (EFAD). This medication is available in generic form. Common side effects include allergic reactions, hyperlipemia, shortness of breath, bluish color to the skin, flushing, headache, dizziness, sleepiness, nausea, vomiting, overheating, sweating, chest and back pain, thrombocytopenia, hypercoagulability, and transient increases in liver enzymes.
The initial infusion rate of Liposyn III 30% in adults should be the equivalent of 0.1 g fat/minute for the first 15 to 30 minutes of infusion. Liposyn III 30% may interact with other drugs. Tell your doctor all medications and supplements you use. During pregnancy, Liposyn III 30% should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
Our Liposyn III 30% (intravenous fat emulsion) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Liposyn III 30 FDA Prescribing Information: Side Effects
Sepsis due to contamination of administration equipment and thrombophlebitis due to vein irritation from concurrently administered hypertonic solutions have been encountered. These are attributable to I.V. therapy in general or to the type of infusion administered.
Adverse reactions directly related to fat emulsions are of two types: (1) immediate (acute) and (2) long term (chronic). In studies of lipid products in general, the following immediate reactions have been noted: Allergic reactions, hyperlipemia, dyspnea, cyanosis, flushing, dizziness, headache, sleepiness, nausea, vomiting, hyperthermia, sweating, chest and back pain, thrombocytopenia (rarely in neonates), hypercoagulability and transient increases in liver enzymes.
The following reactions have been noted with long-term therapy with lipid infusions in general: Hepatomegaly, jaundice due to central lobular cholestasis, splenomegaly, thrombocytopenia, leucopenia, transient increases in liver function tests, overloading syndrome and the deposition of brown pigment ("fat pigment") in the reticuloendothelial tissue of the liver. The significance of this last occurrence and its cause are unknown.
If symptoms and signs of acute respiratory distress develop, appropriate medical intervention should be instituted immediately and the cause of the distress investigated. The parenteral nutrition infusion should be replaced with a dextrose infusion (to prevent rebound hypoglycemia) and checked for the presence of particulate matter and oiling out of the emulsion (see Mixing Instructions For Combined Administration).
Read the entire FDA prescribing information for Liposyn III 30 (Liposyn III 30 Intravenous Far Emulsion)
Additional Liposyn III 30 Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Weight Loss Wisdom
Get tips, recipes and inspiration.